Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02371421 · ClinicalTrials.gov registry record
Genetics of Hyperuricemia Therapy in Hmong
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 80
- Enrollment target
NCT02371421: Completed study, sponsored by University of Minnesota.
NCT02371421 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02371421 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
To pursue this objective, we will be measuring uric acid at baseline and post 14 days of twice daily allopurinol therapy in 30 Hmong participants with documented gout or hyperuricemia and known genotype for key renal transporters of uric acid.
Interventions
- DRUG Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-12 |
What the finished NCT02371421 record still lists
NCT02371421 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Allopurinol is the first listed.
NCT02371421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02371421 about?
NCT02371421 is a clinical study titled "Genetics of Hyperuricemia Therapy in Hmong". To pursue this objective, we will be measuring uric acid at baseline and post 14 days of twice daily allopurinol therapy in 30 Hmong participants with documented gout or hyperuricemia and known genotype for key renal transporters of uric acid.
What is the current status of trial NCT02371421?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2014-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02371421?
The interventions under investigation include: Allopurinol (DRUG).
Who is sponsoring clinical trial NCT02371421?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia